MXCT vs TLRY · rev $38.6M vs rev $821.3M
MaxCyte Inc (MXCT) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported TLRY revenue for 2025-05-31 was $821.3M. Net income was -$2.18B. Revenue was up 4.1% from 2024-05-31 to 2025-05-31. TLRY currently screens at market cap $573.9M.
MXCT currently screens at market cap $124.3M. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the MXCT and TLRY stock pages for the full models.
Not investment advice.